We push the boundaries of science and imagination to discover and develop innovative medicines for patients Learn More

The Science of Saving Lives

about-pic-1_1
about-pic-2_1
about-pic-3
about-pic-4_1

About

Sensei Biotherapeutics is a clinical-stage biopharmaceutical company developing immunotherapies for cancers and infectious disease.

Driven by world class scientists and an entrepreneurial culture focused on rigorous science, innovative treatments, and data-driven decision making, we discover and develop medicines that have the potential to alter the treatment landscape and contribute value to patients and society. The company has developed a unique drug discovery approach, ImmunoPhage™️, that generates powerful and specific immune responses. Its most advanced program, SNS-301, is currently enrolling patients in Phase 1/2 clinical trials.

Senior
Leadership

Driven by world class scientists and an entrepreneurial culture, we have brought together leaders with deep expertise in the core disciplines of biology, immunology, and oncology along with a highly accomplished team of life science business leaders.

Marie-Louise Fjaellskog, M.D., Ph.D.

Chief Medical Officer

John K. Celebi, M.B.A.

President and CEO

Robert Pierce, M.D.

Chief Scientific Officer

In the News

Sorting:
Sort Descending
  • Sensei Biotherapeutics Appoints Deneen Vojta, M.D. to its Board of Directors

    BOSTON, MA    and GAITHERSBURG, MD  –  January 29, 2021  – Sensei Biotherapeutics, Inc., a clinical-stage immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today announced the appointment of Deneen Vojta, M.D. to its Board of Directors. Dr.Read More

  • Sensei Biotherapeutics Announces $30 Million Financing to Advance Clinical Pipeline of Oncology Therapeutics and Proprietary ImmunoPhage™ Platform

    – Round co-led by Apeiron Investment Group and Catalio Capital Management – Proceeds support advancement of lead product candidate and next-generation platform for personalized yet off-the-shelf cancer immunotherapies BOSTON, MA  and ROCKVILLE, MD – January 11, 2021  – Sensei Biotherapeutics, Inc.,Read More

  • Sensei Biotherapeutics Presents Additional Data from Phase 1/2 Clinical Trial of SNS-301 at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

    -  SNS-301 demonstrated prolonged partial response and improvement in immune markers in PD-L1 negative disease patient with 43% tumor reduction -  30+ week stable disease observed in 2 patients BOSTON, Mass. & GAITHERSBURG, Md.--( BUSINESS WIRE )--Sensei Biotherapeutics, Inc., a clinical-stageRead More

In the News

Sorting:
Sort Descending
  • Sensei Biotherapeutics Appoints Deneen Vojta, M.D. to its Board of Directors

    BOSTON, MA    and GAITHERSBURG, MD  –  January 29, 2021  – Sensei Biotherapeutics, Inc., a clinical-stage immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today announced the appointment of Deneen Vojta, M.D. to its Board of Directors. Dr.Read More

  • Sensei Biotherapeutics Announces $30 Million Financing to Advance Clinical Pipeline of Oncology Therapeutics and Proprietary ImmunoPhage™ Platform

    – Round co-led by Apeiron Investment Group and Catalio Capital Management – Proceeds support advancement of lead product candidate and next-generation platform for personalized yet off-the-shelf cancer immunotherapies BOSTON, MA  and ROCKVILLE, MD – January 11, 2021  – Sensei Biotherapeutics, Inc.,Read More

  • Sensei Biotherapeutics Presents Additional Data from Phase 1/2 Clinical Trial of SNS-301 at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

    -  SNS-301 demonstrated prolonged partial response and improvement in immune markers in PD-L1 negative disease patient with 43% tumor reduction -  30+ week stable disease observed in 2 patients BOSTON, Mass. & GAITHERSBURG, Md.--( BUSINESS WIRE )--Sensei Biotherapeutics, Inc., a clinical-stageRead More

Signup For Update

sign up for newsletter and get the latest update